About Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB)
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment. It is also developing NAV5001, an iodine-123 labeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson's disease and other movement disorders with potential use as a diagnostic aid in dementia; diagnostic substances, including technetium 99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, such as therapeutic applications of its Manocept platform, as well as various development programs. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSEAMERICAN:NAVB
CUSIP63937X10
Phone+1-614-7937500
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-688.85%
Return on Equity-38.60%
Return on Assets-25.48%
Miscellaneous
EmployeesN/A
Outstanding Shares162,780,000
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Frequently Asked Questions
What is Navidea Biopharmaceuticals' stock symbol?
Navidea Biopharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "NAVB."
How were Navidea Biopharmaceuticals' earnings last quarter?
Navidea Biopharmaceuticals, Inc. (NYSEAMERICAN:NAVB) issued its quarterly earnings data on Thursday, March, 8th. The biopharmaceutical company reported ($0.03) EPS for the quarter. The biopharmaceutical company had revenue of $0.40 million for the quarter. Navidea Biopharmaceuticals had a negative net margin of 688.85% and a negative return on equity of 38.60%. View Navidea Biopharmaceuticals' Earnings History.
Are investors shorting Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals saw a drop in short interest in the month of April. As of April 13th, there was short interest totalling 4,131,039 shares, a drop of 0.1% from the March 30th total of 4,134,851 shares. Based on an average daily volume of 535,519 shares, the short-interest ratio is currently 7.7 days. Currently, 2.7% of the shares of the company are short sold.
Who are some of Navidea Biopharmaceuticals' key competitors?
Some companies that are related to Navidea Biopharmaceuticals include Adherex Technologies (FRX), ImmunoVaccine (IMMVF), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Tiziana Life Sciences (TILS), Medicure (MPH), Kitrinor Metals (SCYB), Pfenex (PFNX), Oragenics (OGEN), Asterias Biotherapeutics (AST), ProMIS Neurosciences (PMN) and Tissue Regenix Group (TRX).
Who are Navidea Biopharmaceuticals' key executives?
Navidea Biopharmaceuticals' management team includes the folowing people:
- Dr. Michael M. Goldberg, CEO, Pres & Director (Age 59)
- Mr. Jed A. Latkin, CFO, COO, Sec., Treasurer & Principal Accounting officer (Age 44)
- Dr. Frederick O. Cope Ph.D., F.A.C.N., C.N.S., Chief Scientific Officer & Sr. VP (Age 71)
- Mr. William J. Regan, Chief Compliance Officer and Sr. VP of Global Regulatory Affairs & Quality (Age 66)
- Ms. Sharon Correia, Sr. Director of Corp. Communications
Has Navidea Biopharmaceuticals been receiving favorable news coverage?
Press coverage about NAVB stock has trended positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Navidea Biopharmaceuticals earned a news impact score of 0.29 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 45.18 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
How do I buy shares of Navidea Biopharmaceuticals?
Shares of NAVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Navidea Biopharmaceuticals' stock price today?
One share of NAVB stock can currently be purchased for approximately $0.28.
How big of a company is Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals has a market capitalization of $62.36 million.
How can I contact Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals' mailing address is 4995 Bradenton Ave Ste 240, DUBLIN, OH 43017-3552, United States. The biopharmaceutical company can be reached via phone at +1-614-7937500.
MarketBeat Community Rating for Navidea Biopharmaceuticals (NAVB)
MarketBeat's community ratings are surveys of what our community members think about Navidea Biopharmaceuticals and other stocks. Vote "Outperform" if you believe NAVB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NAVB will underperform the S&P 500 over the long term. You may vote once every thirty days.
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/25/2016 forward)
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Earnings History and Estimates Chart
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 3/8/2018 | Q4 2017 | | ($0.03) | | $0.40 million | View | N/A |  |
| 11/7/2017 | Q3 2017 | | ($0.01) | | $0.22 million | View | N/A | |
| 8/8/2017 | Q2 2017 | | ($0.02) | | $0.61 million | View | Listen | |
| 5/9/2017 | Q1 2017 | | ($0.01) | | $0.58 million | View | N/A | |
| 3/29/2017 | Q4 2016 | | ($0.02) | | $3.36 million | View | N/A | |
| 8/4/2016 | Q216 | ($0.03) | ($0.04) | $5.24 million | $5.40 million | View | N/A | |
| 5/17/2016 | Q1 | ($0.03) | ($0.02) | $4.63 million | $4.70 million | View | Listen | |
| 3/23/2016 | Q415 | ($0.04) | ($0.02) | $3.70 million | $4.00 million | View | Listen | |
| 11/4/2015 | Q315 | ($0.04) | ($0.05) | $2.40 million | $3.98 million | View | Listen | |
| 7/30/2015 | Q215 | ($0.04) | ($0.06) | $2.18 million | $2.90 million | View | Listen | |
| 5/12/2015 | Q115 | ($0.03) | ($0.05) | $3.30 million | $2.10 million | View | Listen | |
| 3/5/2015 | | ($0.04) | ($0.05) | $1.95 million | $2.20 million | View | N/A | |
| 3/5/2015 | | ($0.04) | ($0.05) | $1.95 million | $2.20 million | View | N/A | |
| 3/5/2015 | Q414 | ($0.05) | ($0.05) | $2.10 million | $2.20 million | View | Listen | |
| 11/6/2014 | Q314 | ($0.06) | ($0.05) | $1.54 million | $2.30 million | View | Listen | |
| 8/6/2014 | Q214 | ($0.07) | ($0.07) | $1.05 million | $1.05 million | View | Listen | |
| 5/7/2014 | Q114 | ($0.10) | ($0.06) | $0.90 million | $0.7520 million | View | Listen | |
| 3/6/2014 | Q413 | ($0.08) | ($0.10) | $0.74 million | $0.5350 million | View | Listen | |
| 11/6/2013 | Q313 | ($0.08) | $0.09 | $0.97 million | $0.40 million | View | Listen | |
| 8/7/2013 | Q2 2013 | ($0.07) | ($0.09) | $0.55 million | $0.20 million | View | N/A | |
| 5/8/2013 | Q1 2013 | ($0.07) | ($0.06) | $0.02 million | | View | N/A | |
| 3/6/2013 | Q4 2012 | ($0.08) | ($0.08) | | | View | N/A | |
| 11/8/2012 | Q312 | $0.21 | ($0.09) | | | View | N/A | |
| 8/6/2012 | Q2 2012 | ($0.06) | ($0.06) | | | View | N/A | |
| 5/2/2012 | Q1 2012 | ($0.07) | ($0.07) | | | View | N/A | |
| 2/29/2012 | Q4 2011 | ($0.05) | ($0.08) | | | View | N/A | |
| 10/26/2011 | Q3 2011 | ($0.03) | ($0.07) | | | View | N/A | |
| 7/27/2011 | Q2 2011 | ($0.02) | ($0.02) | | | View | N/A | |
| 5/9/2011 | Q1 2011 | ($0.02) | ($0.05) | | | View | N/A | |
| 3/7/2011 | Q4 2010 | ($0.03) | ($0.03) | | | View | N/A | |
| 11/10/2010 | Q3 2010 | ($0.01) | ($0.03) | | | View | N/A | |
| 8/9/2010 | Q2 2010 | ($0.02) | ($0.02) | | | View | N/A | |
| 4/28/2010 | Q1 2010 | ($0.01) | ($0.03) | | | View | N/A | |
| 11/2/2009 | Q3 2009 | ($0.31) | ($0.10) | | | View | N/A | |
| 8/11/2009 | Q2 2009 | ($0.02) | ($0.02) | | | View | N/A | |
| 5/6/2009 | Q1 2009 | | $0.01 | | | View | N/A | |
| 3/10/2009 | Q4 2008 | ($0.03) | ($0.02) | | | View | N/A | |
| 11/5/2008 | Q3 2008 | ($0.02) | ($0.03) | | | View | N/A | |
| 8/4/2008 | Q2 2008 | ($0.03) | ($0.02) | | | View | N/A | |
| 5/1/2008 | Q1 2008 | ($0.01) | ($0.02) | | | View | N/A | |
| 3/19/2008 | Q4 2007 | ($0.01) | ($0.02) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trading and Institutional Ownership History
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/29/2017 | William J Regan | SVP | Buy | 20,000 | $0.53 | $10,600.00 | 172,977 | |
| 5/30/2017 | Jed Latkin | CFO | Buy | 7,600 | $0.44 | $3,344.00 | 50,159 | |
| 5/22/2017 | Jed Latkin | CFO | Buy | 25,359 | $0.45 | $11,411.55 | 31,359 | |
| 12/1/2015 | Brent L Larson | CFO | Sell | 12,500 | $1.50 | $18,750.00 | 222,237 | |
| 10/1/2015 | Brent L Larson | CFO | Sell | 12,500 | $2.27 | $28,375.00 | 247,237 | |
| 9/1/2015 | Brent L Larson | CFO | Sell | 12,500 | $1.88 | $23,500.00 | 259,737 | |
| 6/1/2015 | Brent L Larson | CFO | Sell | 12,500 | $1.24 | $15,500.00 | | |
| 5/29/2015 | Gordon A Troup | Director | Buy | 10,000 | $1.31 | $13,100.00 | | |
| 11/14/2014 | Michael M Goldberg | Director | Buy | 100,000 | $1.08 | $108,000.00 | | |
| 11/10/2014 | Brendan A Ford | Director | Buy | 10,000 | $1.03 | $10,300.00 | | |
| 5/9/2014 | Mark Jerome Pykett | CEO | Buy | 10,000 | $1.34 | $13,400.00 | 292,674 | |
| 3/10/2014 | Brent Larson | CFO | Sell | 41,500 | $1.96 | $81,340.00 | 319,184 | |
| 3/10/2014 | Frederick Cope | SVP | Sell | 15,000 | $1.96 | $29,400.00 | 75,814 | |
| 3/10/2014 | Mark Jerome Pykett | CEO | Sell | 120,000 | $1.96 | $235,200.00 | 282,674 | |
| 11/8/2013 | Brendan Ford | Director | Buy | 20,000 | $1.45 | $29,000.00 | 139,250 | |
| 11/8/2013 | Brent Larson | CFO | Buy | 5,000 | $1.39 | $6,950.00 | 287,304 | |
| 11/8/2013 | Frederick Cope | SVP | Buy | 3,500 | $1.43 | $5,005.00 | 90,814 | |
| 11/8/2013 | Mark Jerome Pykett | CEO | Buy | 10,900 | $1.35 | $14,715.00 | 402,674 | |
| 3/15/2013 | Gordon A Troup | Director | Buy | 7,000 | $2.70 | $18,900.00 | | |
| 3/15/2013 | Mark Jerome Pykett | CEO | Buy | 1,850 | $2.70 | $4,995.00 | | |
| 3/15/2013 | Thomas H Tulip | EVP | Buy | 17,500 | $2.82 | $49,350.00 | | |
| 3/15/2013 | William J Regan | SVP | Buy | 5,000 | $2.71 | $13,550.00 | | |
| 9/14/2012 | Thomas H Tulip | EVP | Buy | 15,000 | $2.70 | $40,500.00 | | |
| 9/12/2012 | Brendan A Ford | Director | Buy | 5,000 | $2.64 | $13,200.00 | | |
| 9/11/2012 | Mark Jerome Pykett | CEO | Buy | 4,000 | $2.64 | $10,560.00 | | |
(Data available from 1/1/2013 forward)
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) News Headlines
| Source: |
|
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB) Income Statement, Balance Sheet and Cash Flow Statement
Navidea Biopharmaceuticals (NYSEAMERICAN NAVB) Stock Chart for Wednesday, April, 25, 2018
Loading chart…
